Most material SEC filings — September 23, 2026

Following Brad Heppner's May 2026 federal fraud conviction, Beneficient announced a strategy to eliminate approximately $130M in contested HCLP debt (principal + accrued interest), convert Heppner's preferred equity ($850M liquidation preference) into 162,132 Class A shares, and void ~$88M in other contractual obligations. The company is pursuing a consensual resolution before Heppner's October 21, 2026 sentencing, with litigation as backup; no definitive agreement has been reached.

Roche's Phase 3 IMAgINATION study of sefaxersen (licensed from Ionis) met its primary endpoint, demonstrating statistically significant proteinuria reduction versus placebo at 37 weeks in 459 patients with IgA nephropathy. The study continues blinded to week 105 to assess kidney function preservation (eGFR); interim data will be presented at medical congresses and shared with regulators. Under the Roche license agreement, Ionis receives upfront, milestone, and royalty payments—specific amounts not disclosed in this filing.

Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War (through MTEC/NMRC) specifically for Phase 3 clinical development of AP-SA02, a bacteriophage therapeutic for complicated Staphylococcus aureus bacteremia. This is the first Phase 3-directed tranche under a broader DoW award; cumulative DoW funding for AP-SA02 now totals $32.4 million ($28.7M previously announced plus this $3.7M increment). The Phase 3 study is anticipated to initiate in H2 2026.

Ivanhoe Electric filed a Form 8-K with consents from 10 third-party engineering/consulting firms (BBA, Worley, Burns McDonnell, Haley Aldrich, INTERA, KCB, Life Cycle Geo, Met Engineering, Paterson Cooke, Stantec, Tetra Tech) authorizing use of their names and a September 2026 S-K 1300 Preliminary Feasibility Study for the Santa Cruz Copper Project in Arizona. The PFS includes mineral resource estimates of 748.5 Mt indicated and 422.0 Mt inferred copper resource; mineral reserves of 140.1 Mt probable; 24-year mine life producing ~58,000 t/y copper cathode; $2.85B total life-of-mine capital costs ($1.43B initial, $1.42B sustaining); after-tax NPV of $1.52B at 8% discount rate and IRR of 18.7%; and $4.53B total operating costs. No specific dollar transactions between counterparties are disclosed; this is a pure technical disclosure filing.

Michael Steib, former president and CEO of TEGNA (acquired by Nexstar in March 2026) and former CEO of Artsy and XO Group/The Knot, was appointed CEO of Angi effective immediately on September 22, 2026, succeeding Jeff Kip. Joey Levin transitioned from Executive Chairman to Chairman. Kip will serve as advisor for six months. No financial terms, severance amounts, or equity compensation details were disclosed in this announcement.

Astrana Health disclosed a material cybersecurity incident on September 22, 2026, filed via Form 8-K on September 23, 2026 under Item 1.05. The filing provides no specific details regarding the nature of the breach, affected data, number of individuals impacted, remediation costs, or timeline for resolution. The 8-K references only the incident classification, not scope or financial impact.